Integra LifeSciences Amends $150M Accounts Receivable Facility

Integra LifeSciences Holdings Corporation's subsidiaries entered into amendments for their $150 million accounts receivable securitization facility on April 10, 2026. These amendments, including Amendment No. 8 to the Receivables Financing Agreement and Amendment No. 1 to the Purchase and Sale Agreement, update the existing facility. The facility, originally established in December 2018, continues to provide liquidity and funding for the company's ongoing business needs and helps reduce outstanding revolving borrowings.